A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders

RemeGen

Status and phase: Enrolling; Phase 3

Conditions: Neuromyelitis Optica Spectrum Disorders

Treatments: Biological: Placebo; Biological: RC18 160 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT03330418

C009NMOSDCLLI

Details and patient eligibility

About

The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Neuromyelitis Optica Spectrum Disorders.

Enrollment: 166 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Meet the 2015 international consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders and astrocyte water channel aquaporin-4 (AQP4) antibody positivity.
• EDSS 0-7.5
• Clinical evidence of at least 2 relapses within the first two years of randomization and/ or 1 relapse within the first one year of randomization
• Consent to use effective contraception during the study period (women of childbearing age)
• Voluntarily signed informed consent

Exclusion criteria

• Abnormal laboratory parameters need to be excluded, including but not limited to:
• Currently suffering from active hepatitis or serious liver disease and medical history
• Patients were treated with rituximab or other monoclonal antibodies within 6 months prior to randomization .
• Any concomitant disease other than neuromyelitis optica（NMO）/ neuromyelitis optica Spectrum disorders（NMOSD）that required treatment with lucocorticoid.
• pregnant , lactating women and men or women who have birth plans during the research;
• Have a history of allergic reaction to contrast agent for parenteral administration and human biological medicines.
• Receipt of intravenous immune globulin （ IVIG） within 28 days prior to randomization.
• Receipt of any of the following prior to randomization: Azathioprine,Cyclosporin, Methotrexate Mitoxantrone,Cyclophosphamide,Tocilizumab,Tacrolimus,Mycophenolate,and Patients discontinued more than 5 times the half-life of the drug before they could get into the group .If the patients taking leflunomide and teriflunomide,they should need to take colestyramine for elution.
• Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking shorter time ).
• The patients have severe psychiatric symptoms and are not compatible with clinical studies
• Malignant tumor patients ;
• patients experienced any of the following events within 12 weeks before screening : myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association class IV heart failure
• Patients can't accept magnetic resonance imaging inspection during the trial.
• Infection with herpes zoster or HIV virus at the screening;
• The anti-hepatitis C virus （anti-HCV） of patients show positive;
• Investigator considers candidates not appropriating for the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

166 participants in 2 patient groups

Placebo Comparator

Experimental group

Description:

Participants received placebo weekly administered subcutaneously for 48 times in the double-blind treatment period.Once the participants relapse,they should advance to the open phase.All participants were treated with the test drugs.

Treatment:

Biological: Placebo

RC18 160 mg

Experimental group

Description:

Patients received the test group RC18 160mg weekly administered subcutaneously for 48 times.Starting with the forty-ninth dose,the trial went into the open phase . All participants were treated with the test drugs.

Treatment:

Biological: RC18 160 mg